On April 2, 2026, OSR Holdings, Inc. (NASDAQ: OSRH) announced that it has entered into a Binding Term Sheet with BCM Europe AG (BCME) regarding a revised global exclusive license arrangement for its cancer immunotherapy product, VXM01. This agreement, effective March 27, 2026, supersedes a previous term sheet dated January 13, 2025. Under the new structure, OSR Holdings will act as a direct counterparty alongside its wholly-owned subsidiary, Vaximm AG, and will be the primary recipient of milestone and royalty payments. The agreement stipulates that BCME will be responsible for up to $815 million in milestone payments, which will be paid directly to OSR Holdings. Additionally, OSR Holdings will provide Vaximm with a development financing facility of up to $30 million to support the clinical development of VXM01. The execution of a definitive agreement is subject to customary conditions, including due diligence and board approvals. This strategic move is expected to enhance OSR Holdings' financial position and operational capabilities in the oncology market, positioning the company for significant growth as it advances VXM01 through clinical trials and towards commercialization.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.